BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 38378604)

  • 1. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
    Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
    J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term serial circulating tumor DNA assessment predicts therapeutic efficacy for patients with advanced pancreatic cancer.
    Motobayashi H; Kitahata Y; Okada KI; Miyazawa M; Ueno M; Hayami S; Miyamoto A; Shimizu A; Sato M; Yoshimura T; Nakamura Y; Takemoto N; Nakai T; Hyo T; Matsumoto K; Yamaue H; Kawai M
    J Cancer Res Clin Oncol; 2024 Jan; 150(2):35. PubMed ID: 38277079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma.
    Guan S; Deng G; Sun J; Han Q; Lv Y; Xue T; Ding L; Yang T; Qian N; Dai G
    Front Oncol; 2022; 12():926260. PubMed ID: 36081557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
    Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
    BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Ecker BL; Tao AJ; Janssen QP; Walch HS; Court CM; Balachandran VP; Crane CH; D'Angelica MI; Drebin JA; Kingham TP; Soares KC; Iacobuzio-Donahue CA; Vakiani E; Gonen M; O'Reilly EM; Varghese AM; Jarnagin WR; Wei AC
    Clin Cancer Res; 2023 Apr; 29(7):1368-1374. PubMed ID: 36795432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma.
    Dayimu A; Di Lisio L; Anand S; Roca-Carreras I; Qian W; Al-Mohammad A; Basu B; Valle JW; Jodrell D; Demiris N; Corrie P
    Br J Cancer; 2023 May; 128(9):1672-1680. PubMed ID: 36813867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.
    Strijker M; Soer EC; de Pastena M; Creemers A; Balduzzi A; Beagan JJ; Busch OR; van Delden OM; Halfwerk H; van Hooft JE; van Lienden KP; Marchegiani G; Meijer SL; van Noesel CJ; Reinten RJ; Roos E; Schokker S; Verheij J; van de Vijver MJ; Waasdorp C; Wilmink JW; Ylstra B; Besselink MG; Bijlsma MF; Dijk F; van Laarhoven HW
    Int J Cancer; 2020 Mar; 146(5):1445-1456. PubMed ID: 31340061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study.
    Evrard C; Ingrand P; Rochelle T; Martel M; Tachon G; Flores N; Randrian V; Ferru A; Haineaux PA; Goujon JM; Karayan-Tapon L; Tougeron D
    Dig Liver Dis; 2023 Nov; 55(11):1562-1572. PubMed ID: 37308396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.
    Pietrasz D; Wang-Renault S; Taieb J; Dahan L; Postel M; Durand-Labrunie J; Le Malicot K; Mulot C; Rinaldi Y; Phelip JM; Doat S; Blons H; de Reynies A; Bachet JB; Taly V; Laurent-Puig P
    Br J Cancer; 2022 Feb; 126(3):440-448. PubMed ID: 34811505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma.
    Bachet JB; Blons H; Hammel P; Hariry IE; Portales F; Mineur L; Metges JP; Mulot C; Bourreau C; Cain J; Cros J; Laurent-Puig P
    Clin Cancer Res; 2020 Oct; 26(19):5208-5216. PubMed ID: 32605910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic and Prognostic Values of KRAS Mutations on EUS-FNA Specimens and Circulating Tumor DNA in Patients With Pancreatic Cancer.
    Wang R; Zhao Y; Wang Y; Zhao Z; Chen Q; Duan Y; Xiong S; Luan Z; Wang J; Cheng B
    Clin Transl Gastroenterol; 2022 May; 13(5):e00487. PubMed ID: 35351843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
    Renouf DJ; Loree JM; Knox JJ; Topham JT; Kavan P; Jonker D; Welch S; Couture F; Lemay F; Tehfe M; Harb M; Aucoin N; Ko YJ; Tang PA; Ramjeesingh R; Meyers BM; Kim CA; Du P; Jia S; Schaeffer DF; Gill S; Tu D; O'Callaghan CJ
    Nat Commun; 2022 Aug; 13(1):5020. PubMed ID: 36028483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker.
    Pietrasz D; P├ęcuchet N; Garlan F; Didelot A; Dubreuil O; Doat S; Imbert-Bismut F; Karoui M; Vaillant JC; Taly V; Laurent-Puig P; Bachet JB
    Clin Cancer Res; 2017 Jan; 23(1):116-123. PubMed ID: 27993964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
    Kruger S; Heinemann V; Ross C; Diehl F; Nagel D; Ormanns S; Liebmann S; Prinz-Bravin I; Westphalen CB; Haas M; Jung A; Kirchner T; von Bergwelt-Baildon M; Boeck S; Holdenrieder S
    Ann Oncol; 2018 Dec; 29(12):2348-2355. PubMed ID: 30346475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.